Aggressive use of corticosteroids for the management of toxicities associated with chimeric antigen receptor (CAR) T-cell therapy may worsen survival in patients with large B-cell lymphoma (LBCL), according to a new retrospective study. In the pivotal trial that led to approvals of the CAR T-cell therapy axicabtagene clioleucel (axi-cel) in Australia, the US, UK, and ...
Corticosteroid use may worsen outcomes in CAR T-cell therapy for lymphoma
By Dave Levitan
11 Feb 2021